Stemline Therapeutics, Inc.

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. 2.18%69.310.0%$2166.31m
NVAXNovavax, Inc. 8.42%144.5096.5%$1227.91m
SRNESorrento Therapeutics, Inc. -4.51%12.422.8%$766.55m
GILDGilead Sciences, Inc. 0.39%68.451.0%$570.20m
AMGNAmgen, Inc. 0.26%239.471.3%$469.75m
REGNRegeneron Pharmaceuticals, Inc. 0.38%613.192.7%$386.22m
VRTXVertex Pharmaceuticals, Inc. -0.09%266.901.9%$352.83m
BIIBBiogen, Inc. 0.47%289.911.6%$351.76m
BNTXBioNTech SE -1.59%69.870.0%$347.41m
ILMNIllumina, Inc. -2.55%344.523.5%$342.80m
ATNMActinium Pharmaceuticals, Inc. -0.86%9.8313.3%$234.70m
VXRTVaxart, Inc. 1.10%9.190.0%$214.56m
EBSEmergent BioSolutions, Inc. -1.30%133.186.4%$196.81m
MCRBSeres Therapeutics, Inc. -3.81%27.493.6%$179.77m
ALXNAlexion Pharmaceuticals, Inc. 1.18%103.092.0%$164.99m

Company Profile

Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in a solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY.